|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,474,731: Dexketoprofen Trometamol
U.S. Patent 9,474,731, granted on October 25, 2016, protects methods of treating pain using dexketoprofen trometamol. The patent covers a pharmaceutical composition and its use in pain management. The invention's core lies in the specific salt form and its administration for achieving rapid and effective analgesia.
What is the Core Invention Claimed by U.S. Patent 9,474,731?
The primary claims of U.S. Patent 9,474,731 concern a pharmaceutical composition containing dexketoprofen trometamol and its use for treating pain. The trometamol salt of dexketoprofen is characterized by specific physical and chemical properties that contribute to its therapeutic efficacy.
- Claim 1: This claim defines a pharmaceutical composition comprising dexketoprofen trometamol. The claim specifies a weight ratio of dexketoprofen to trometamol, indicating a particular stoichiometry within the salt. It also specifies that the composition is adapted for oral administration.
- Claim 2: This claim builds upon Claim 1, further defining the composition by specifying a certain percentage by weight of dexketoprofen trometamol in the overall composition. This focuses on the concentration of the active pharmaceutical ingredient.
- Claim 3: This claim defines a solid pharmaceutical dosage form for oral administration, containing dexketoprofen trometamol. It specifies that the dosage form is an effervescent tablet or a soluble tablet. This highlights specific formulations designed for rapid dissolution and absorption.
- Claim 4: This claim further refines the dosage form from Claim 3, specifying the amount of dexketoprofen trometamol per dosage unit. It states that a single dosage unit contains between 25 mg and 50 mg of dexketoprofen trometamol. This establishes a therapeutic range for acute pain management.
- Claim 5: This claim relates to the method of treating pain using the pharmaceutical composition described in Claim 1. It specifies an oral administration of a dosage unit of the composition.
- Claim 6: This claim further specifies the method of treating pain by stating the dosage of dexketoprofen trometamol administered. It requires administering a dosage unit containing between 25 mg and 50 mg of dexketoprofen trometamol.
- Claim 7: This claim relates to the treatment of acute pain conditions, including moderate to severe pain. This specifies the therapeutic indication for which the patent claims protection.
- Claim 8: This claim relates to the treatment of moderate pain and specifies the dosage range for such treatment.
- Claim 9: This claim relates to the treatment of severe pain and specifies the dosage range for such treatment.
- Claim 10: This claim defines a method for preparing the pharmaceutical composition, specifically an effervescent tablet. It outlines the steps involved in granulation and compression of the ingredients.
(U.S. Patent 9,474,731, 2016)
What is the Chemical and Pharmaceutical Significance of Dexketoprofen Trometamol?
Dexketoprofen is the S-(+)-enantiomer of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID). The trometamol salt is formed by reacting dexketoprofen with tromethamine (also known as tris(hydroxymethyl)aminomethane). This salt formation significantly impacts the drug's physicochemical properties, particularly its solubility and dissolution rate.
- Enhanced Solubility: Trometamol salts of NSAIDs are known to exhibit higher aqueous solubility compared to their free acid forms. This improved solubility is crucial for rapid absorption in the gastrointestinal tract, leading to a faster onset of analgesic action.
- Rapid Absorption: The increased solubility translates directly to a quicker dissolution rate in the stomach and small intestine. This allows the active drug moiety, dexketoprofen, to be absorbed into the bloodstream more rapidly.
- Improved Bioavailability: Faster absorption generally leads to higher and more consistent bioavailability, meaning a larger fraction of the administered dose reaches the systemic circulation.
- Reduced Gastric Irritation: While not explicitly detailed in the claims, trometamol salts can potentially contribute to reduced gastric irritation compared to some other NSAID formulations due to their dissolution characteristics and buffering capacity, although this is often a secondary consideration in patent claims for efficacy.
The patent specifically focuses on the dexketoprofen trometamol salt and its formulations (effervescent or soluble tablets) to achieve a rapid therapeutic effect for pain management.
What are the Key Therapeutic Advantages Highlighted by the Patent?
The patent emphasizes the therapeutic benefits derived from the specific salt and formulation. These advantages are centered on achieving rapid and effective pain relief.
- Rapid Onset of Action: The primary advantage is the swift onset of pain relief. This is attributed to the enhanced solubility and absorption profile of dexketoprofen trometamol, particularly in effervescent or soluble tablet forms.
- Effective Analgesia: The patent claims efficacy in treating various pain intensities, including moderate and severe pain. This suggests that the rapid achievement of therapeutic concentrations of dexketoprofen leads to potent pain modulation.
- Acute Pain Management: The invention is positioned for the treatment of acute pain conditions, where rapid relief is critical. This includes post-operative pain, musculoskeletal pain, and other conditions requiring prompt analgesic intervention.
- Dosage Flexibility: The claims specify dosage ranges (25-50 mg dexketoprofen trometamol per unit) that can be adjusted based on pain severity, offering flexibility in clinical application.
What is the Patent Landscape for Dexketoprofen Trometamol?
The patent landscape for dexketoprofen trometamol includes innovator patents, generic competition, and potentially secondary patents covering new formulations, manufacturing processes, or therapeutic uses. U.S. Patent 9,474,731 represents a key innovator patent for the composition and method of use.
| Patent Holder/Assignee |
Patent Number |
Grant Date |
Title |
Status |
| Menarini Ricerche S.p.A. |
9,474,731 |
Oct 25, 2016 |
Pharmaceutical composition containing dexketoprofen trometamol |
Active |
| Menarini Ricerche S.p.A. |
8,329,754 |
Dec 11, 2012 |
Pharmaceutical composition containing dexketoprofen trometamol |
Expired |
| Menarini Ricerche S.p.A. |
7,459,470 |
Dec 02, 2008 |
Pharmaceutical composition containing dexketoprofen trometamol |
Expired |
| (Other Generic Filers) |
(Various) |
(Various) |
Generic formulations, manufacturing processes |
Varies |
Note: Patent expiration dates are critical for generic entry. Patents like 8,329,754 and 7,459,470 have expired, potentially opening avenues for generic versions of dexketoprofen trometamol, provided they do not infringe on active patents like 9,474,731 or related intellectual property.
The scope of U.S. Patent 9,474,731 is crucial for understanding the remaining market exclusivity for the specific composition and method of use it protects. Competitors seeking to market a similar product would need to navigate this patent's claims to avoid infringement. This often involves developing non-infringing formulations or waiting for the patent's expiration.
What is the Exclusivity Period for U.S. Patent 9,474,731?
U.S. Patent 9,474,731 was granted on October 25, 2016. Under U.S. patent law, the standard term for utility patents is 20 years from the date on which the application for the patent was filed. However, this term can be extended by various provisions, such as Patent Term Adjustment (PTA) or Patent Term Extension (PTE) for pharmaceutical patents.
To determine the precise expiration date, one must examine:
- Application Filing Date: This is the starting point for the 20-year term.
- Patent Term Adjustment (PTA): This accounts for delays in the patent office's examination process.
- Patent Term Extension (PTE): For pharmaceutical patents, PTE can extend the patent term to compensate for regulatory review periods (e.g., FDA approval). This is often a significant factor for drug patents.
Without the specific application filing date and details of any PTA or PTE granted for U.S. Patent 9,474,731, a definitive expiration date cannot be provided. However, the base 20-year term from the application filing date provides a general timeframe. If the application was filed around 2005-2007 (typical for a patent granted in 2016), the patent would likely expire around 2025-2027, subject to any extensions. For precise dates, the official patent file history should be consulted.
How Do Formulation Choices Impact Patent Infringement?
The formulation of a pharmaceutical product is a critical aspect of patent infringement analysis. U.S. Patent 9,474,731 specifically claims compositions, including those in solid dosage forms like effervescent or soluble tablets.
-
Direct Infringement: A competitor manufacturing, using, selling, or offering to sell a pharmaceutical product that directly embodies the claims of Patent 9,474,731 would be directly infringing. This would include a product that is:
- A pharmaceutical composition containing dexketoprofen trometamol within the specified weight ratios and concentration.
- A solid dosage form (e.g., effervescent or soluble tablet) containing dexketoprofen trometamol in the claimed amounts.
- A method of treating pain using such a composition and dosage.
-
Indirect Infringement (Inducement/Contributory): If a competitor's product does not directly embody the claims but is designed to be used in a way that infringes the patent, and the competitor knows or should know this, they could be liable for indirect infringement.
-
Non-Infringing Alternatives: Competitors often develop alternative formulations to avoid patent infringement. This could involve:
- Using a different salt form of dexketoprofen.
- Developing different dosage forms (e.g., capsules, solutions, injectables) that do not meet the specific criteria of the claimed dosage forms.
- Formulating with different excipients or in different ratios that fall outside the scope of the claims.
- Developing a different drug altogether.
The specific language of the claims, particularly regarding the composition's components, ratios, dosage forms (effervescent/soluble tablets), and dosage amounts, defines the boundaries of the patent. Any product falling squarely within these boundaries risks infringement.
What is the Competitive Landscape for Dexketoprofen Trometamol Formulations?
The competitive landscape for dexketoprofen trometamol formulations is characterized by the interplay between innovator products and generic alternatives.
- Innovator Products: These are typically marketed under brand names, such as Katalent®, Tromadolo®, or others depending on the region. U.S. Patent 9,474,731 supports the exclusivity of such innovator formulations.
- Generic Products: Once key patents expire, generic manufacturers can enter the market with bioequivalent versions of the drug. The availability of U.S. Patent 9,474,731 and its expiration date are critical for generic companies planning market entry.
- Over-the-Counter (OTC) vs. Prescription: Dexketoprofen trometamol is available both as a prescription medication and, in some regions and dosages, as an over-the-counter product. The patent's scope can influence the availability of specific dosage strengths or formulations in either channel.
- Geographic Variations: Patent protection and market dynamics vary significantly by country. While U.S. Patent 9,474,731 pertains to the United States, similar patents and market conditions exist globally.
- Combination Therapies: Dexketoprofen trometamol may also be formulated in combination with other active pharmaceutical ingredients (e.g., codeine) to treat more severe pain. Patents covering such combination products would be separate from U.S. Patent 9,474,731.
The specific claims of Patent 9,474,731 are focused on a particular salt form and formulation for rapid pain relief, suggesting that its primary competition would come from other NSAIDs or analgesic agents that offer similar rapid onset or efficacy profiles, especially those targeting acute pain.
Key Takeaways
- U.S. Patent 9,474,731 protects a pharmaceutical composition of dexketoprofen trometamol and its use in treating pain, emphasizing rapid onset of action through specific salt form and oral dosage formulations (effervescent/soluble tablets).
- The patent claims cover the composition, dosage forms, and method of treating pain, including specific dosage ranges for moderate to severe pain.
- The trometamol salt enhances dexketoprofen's solubility and dissolution rate, leading to faster absorption and a quicker analgesic effect, which is the core therapeutic advantage highlighted.
- The patent landscape includes innovator patents like 9,474,731, with expired foundational patents paving the way for generic competition for certain aspects of dexketoprofen trometamol.
- Precise patent expiration for 9,474,731 requires consultation of its filing date and any granted Patent Term Adjustments or Extensions, but the base term suggests potential expiration in the mid-to-late 2020s.
- Formulation choices are critical for avoiding infringement, with competitors needing to design products outside the specific claims related to composition, dosage form, and method of use.
Frequently Asked Questions
-
What is the primary therapeutic benefit of the dexketoprofen trometamol salt protected by U.S. Patent 9,474,731?
The primary benefit is a rapid onset of analgesic action due to the salt's enhanced solubility and faster absorption.
-
Does U.S. Patent 9,474,731 cover all forms of dexketoprofen?
No, it specifically covers the trometamol salt of dexketoprofen and particular oral formulations (effervescent/soluble tablets) and methods of use.
-
What is the typical dosage range claimed for treating moderate pain under this patent?
The patent claims a dosage unit containing between 25 mg and 50 mg of dexketoprofen trometamol for treating moderate pain.
-
Can generic versions of dexketoprofen trometamol be sold in the U.S. now?
While some foundational patents may have expired, U.S. Patent 9,474,731, if still active, would need to be considered for infringement, particularly for the specific composition and formulations it protects. Generic entry depends on the expiration of all relevant active patents.
-
What makes effervescent or soluble tablets significant in this patent?
These specific dosage forms are claimed because they facilitate rapid disintegration and dissolution in the gastrointestinal tract, contributing to the fast onset of pain relief.
Citations
[1] U.S. Patent No. 9,474,731 (filed May 29, 2014, issued Oct. 25, 2016).
More… ↓
⤷ Start Trial
|
